Core Insights - Harrow is launching the Harrow Access for All (HAFA) program to enhance patient access to its ophthalmic medications, building on the success of the VEVYE Access for All (VAFA) initiative [1][2][4] Summary by Sections HAFA Program Overview - HAFA aims to provide a unified access point for Harrow's comprehensive ophthalmic portfolio, including branded, authorized generics, and compounded medications, set to launch in late 2025 [3][4] - The program is designed to improve affordability and streamline the prescribing process, ultimately supporting better patient outcomes and greater efficiency for physicians [3][4] Program Highlights - Eligible commercially insured patients may pay as little as $0, with out-of-pocket costs capped at $59 for all eligible patients, ensuring affordability regardless of coverage status [5] - HAFA will be implemented in three phases, with Phase 1 launching in Q4 2025, covering the majority of Harrow's specialty product portfolio [5] - Phase 2 is expected in the first half of 2026, expanding the portfolio of authorized generics, while Phase 3 in 2027 will extend across Harrow's full range of specialty, AGx, and compounded medicines [5] Technology and Efficiency - The HarrowAccess.com portal will streamline the prescribing process, allowing prescribers to manage prescriptions efficiently and reducing administrative burdens [10] - The platform will integrate with providers' EMR systems, ensuring automatic access to HAFA benefits for patients without additional steps [7][10] Commitment to Patient Access - The CEO of Harrow emphasized the company's commitment to reducing access barriers in ophthalmology, aiming to ensure that every patient can access sight-preserving medications without delay [4] - The program is seen as a significant step towards addressing the challenges of access and affordability in prescription medications, which have been longstanding issues in the industry [7]